Harvard Apparatus Regenerative Technology PE Ratio 2013-2025 | HRGN
Current and historical p/e ratio for Harvard Apparatus Regenerative Technology (HRGN) from 2013 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Harvard Apparatus Regenerative Technology PE ratio as of June 26, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Harvard Apparatus Regenerative Technology PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-25 | 1.60 | 0.00 | |
| 2025-03-31 | 1.93 | $-0.40 | 0.00 |
| 2024-12-31 | 2.98 | $-0.45 | 0.00 |
| 2024-09-30 | 5.68 | $-0.58 | 0.00 |
| 2024-06-30 | 2.92 | $-0.58 | 0.00 |
| 2024-03-31 | 3.00 | $-0.59 | 0.00 |
| 2023-12-31 | 4.99 | $-0.68 | 0.00 |
| 2023-09-30 | 5.36 | $-0.67 | 0.00 |
| 2023-06-30 | 3.65 | $-0.65 | 0.00 |
| 2023-03-31 | 6.45 | $-0.58 | 0.00 |
| 2022-12-31 | 5.50 | $-0.54 | 0.00 |
| 2022-09-30 | 7.10 | $-0.97 | 0.00 |
| 2022-06-30 | 4.65 | $-0.95 | 0.00 |
| 2022-03-31 | 4.90 | $-0.87 | 0.00 |
| 2021-12-31 | 2.30 | $-0.76 | 0.00 |
| 2021-09-30 | 3.00 | $-0.32 | 0.00 |
| 2021-06-30 | 1.26 | $-0.31 | 0.00 |
| 2021-03-31 | 1.34 | $-0.41 | 0.00 |
| 2020-12-31 | 1.25 | $-0.56 | 0.00 |
| 2020-09-30 | 1.60 | $-0.66 | 0.00 |
| 2020-06-30 | 2.51 | $-0.92 | 0.00 |
| 2020-03-31 | 4.00 | $-1.15 | 0.00 |
| 2019-12-31 | 2.01 | $-1.23 | 0.00 |
| 2019-09-30 | 2.60 | $-1.34 | 0.00 |
| 2019-06-30 | 2.12 | $-1.38 | 0.00 |
| 2019-03-31 | 2.35 | $-1.56 | 0.00 |
| 2018-12-31 | 2.06 | $-1.80 | 0.00 |
| 2018-09-30 | 3.12 | $-2.09 | 0.00 |
| 2018-06-30 | 4.52 | $-1.72 | 0.00 |
| 2018-03-31 | 3.10 | $-3.17 | 0.00 |
| 2017-12-31 | 0.87 | $-5.41 | 0.00 |
| 2017-09-30 | 6.18 | $-8.80 | 0.00 |
| 2017-06-30 | 8.24 | $-12.40 | 0.00 |
| 2017-03-31 | 7.34 | $-13.80 | 0.00 |
| 2016-12-31 | 17.80 | $-14.60 | 0.00 |
| 2016-09-30 | 21.60 | $-14.00 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.025B | $0.000B |
| Harvard Apparatus Regenerative Technology Inc. provide greater clarity and visibility for its regenerative technology and expanding strategy on rejuvenation. Harvard Apparatus Regenerative Technology Inc., formerly known as Biostage Inc., is based in HOLLISTON, Mass. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.850B | 26.98 |
| Elevance Health (ELV) | United States | $84.468B | 10.90 |
| CVS Health (CVS) | United States | $83.959B | 10.44 |
| Cencora (COR) | United States | $56.658B | 19.71 |
| DiDi Global (DIDIY) | China | $22.826B | 24.25 |
| Natera (NTRA) | United States | $22.415B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.653B | 17.56 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.432B | 0.00 |
| Solventum (SOLV) | United States | $12.967B | 13.73 |
| CochLear (CHEOY) | Australia | $12.826B | 0.00 |
| ICON (ICLR) | Ireland | $11.783B | 10.95 |
| Revvity (RVTY) | United States | $11.516B | 19.82 |
| Viatris (VTRS) | United States | $10.434B | 3.58 |
| Avantor (AVTR) | United States | $9.254B | 13.45 |
| HealthEquity (HQY) | United States | $8.991B | 39.38 |
| Medpace Holdings (MEDP) | United States | $8.943B | 23.75 |
| Sonic Healthcare (SKHHY) | Australia | $8.181B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.378B | 14.46 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.305B | 25.35 |
| BrightSpring Health Services (BTSG) | United States | $3.975B | 36.47 |
| Sotera Health (SHC) | United States | $3.162B | 17.97 |
| Surgery Partners (SGRY) | United States | $2.782B | 36.18 |
| Alignment Healthcare (ALHC) | United States | $2.710B | 0.00 |
| Concentras Parent (CON) | United States | $2.631B | 15.21 |
| Organon (OGN) | United States | $2.600B | 2.76 |
| GeneDx Holdings (WGS) | United States | $2.537B | 97.72 |
| PACS (PACS) | United States | $1.951B | 0.00 |
| Ardent Health (ARDT) | United States | $1.877B | 8.00 |
| Premier (PINC) | United States | $1.799B | 13.66 |
| Progyny (PGNY) | United States | $1.792B | 39.45 |
| GoodRx Holdings (GDRX) | United States | $1.754B | 35.07 |
| Teladoc Health (TDOC) | United States | $1.328B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.171B | 8.91 |
| Establishment Labs Holdings (ESTA) | $1.084B | 0.00 | |
| CareDx (CDNA) | United States | $1.064B | 16.62 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.999B | 0.00 |
| Agilon Health (AGL) | United States | $0.902B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.840B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.806B | 7.54 |
| Nutex Health (NUTX) | United States | $0.670B | 10.14 |
| LifeMD (LFMD) | United States | $0.584B | 0.00 |
| Embecta (EMBC) | United States | $0.580B | 3.91 |
| InnovAge Holding (INNV) | United States | $0.516B | 0.00 |
| Enhabit (EHAB) | United States | $0.476B | 39.17 |
| Auna S.A (AUNA) | Luxembourg | $0.464B | 10.45 |
| Sonida Senior Living (SNDA) | United States | $0.455B | 0.00 |
| Omada Health (OMDA) | $0.452B | 0.00 | |
| SBC Medicals (SBC) | United States | $0.442B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.301B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.258B | 0.00 |
| Beauty Health (SKIN) | United States | $0.242B | 0.00 |
| Oncology Institute (TOI) | United States | $0.192B | 0.00 |
| So-Young (SY) | China | $0.189B | 0.00 |
| DocGo (DCGO) | United States | $0.165B | 27.00 |
| Pheton Holdings (PTHL) | China | $0.113B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.095B | 0.00 |
| KindlyMD (NAKA) | United States | $0.085B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.075B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| ModivCare (MODV) | United States | $0.049B | 0.00 |
| Biodesix (BDSX) | United States | $0.040B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.038B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.036B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |